Table 3.
Associations of vascular and phosphate biomarkers with pulse wave velocity and coronary artery calcification in incident hemodialysis participants
| Variables | Pulse wave velocity (log m/s) |
Coronary artery calcification |
|||
|---|---|---|---|---|---|
| N | Percent difference for baseline associations (95% CI) | Percent difference for associations over follow-up (95% CI) | N | Baseline associations PR (95% CI) | |
| dp-ucMGP, log ppm | |||||
| Unadjusted | 272 | 0.50 (−3.9 to 5.9) | −0.40 (−4.2–3.4) | 281 | 1.12 (1.00–1.25)a |
| Model 1b | 272 | 0.20 (−4.2 to 4.7) | −0.60 (−4.2–3.1) | 281 | 1.03 (0.92–1.15) |
| Model 2c | 272 | 0.30 (−3.9 to 4.5) | −1.3 (−5.2 to 2.5) | 281 | 1.02 (0.92–1.14) |
| OPG, 5 pmol/l | |||||
| Unadjusted | 287 | 10.0 (6.5–14.0)a | 9.0 (5.5–12.0)a | 298 | 1.22 (1.13–1.31)a |
| Model 1b | 287 | 6.0 (2.0–9.5)a | 5.0 (1.5–8.0)a | 298 | 1.11 (1.03–1.19)a |
| Model 2c | 287 | 3.0 (−0.50 to 7.0) | 3.7 (0.50–7.0)a | 298 | 1.09 (1.01–1.17)a |
| Fetuin-A, g/l | |||||
| Unadjusted | 287 | −20.7 (−40.7 to −8.0)a | −19.6 (−37.0 to −1.9)a | 298 | 0.61 (0.34–1.08) |
| Model 1b | 287 | −6.6 (−25.6 to 12.4) | −6.5 (−22.6 to 9.6) | 298 | 1.04 (0.62–1.73) |
| Model 2c | 287 | 0.10 (−17.8 to 18.0) | −4.5 (−20.2 to 11.2) | 298 | 1.25 (0.74–2.11) |
| FGF23, 100 log RU/ml | |||||
| Unadjusted | 286 | −4.9 (−8.7 to −1.0)a | −3.9 (−7.1 to −0.60)a | 297 | 1.08 (0.98–1.18) |
| Model 1b | 286 | −2.5 (−6.1 to 1.2) | −2.1 (−5.0 to 0.80) | 297 | 1.14 (1.05–1.25)a |
| Model 2c | 286 | −2.8 (−6.3 to 0.80) | −2.9 (−5.7 to −0.10)a | 297 | 1.12 (1.02–1.34)a |
dp-ucMGP, desphospho-uncarboxylated matrix Gla protein; FGF23, fibroblast growth factor 23; HR, hazard ratio; OPG, osteoprotegerin; PR, prevalence ratio.
P < 0.05 (statistically significant).
Model 1 is adjusted for model including age, sex, and race.
Model 2 is adjusted for all variables in Model 1 plus the Charlson comorbidity index, albumin and C-reactive protein, body mass index, and systolic blood pressure; for dp-ucMGP, Model 2 is also adjusted for dietary vitamin K intake; for FGF23, Model 2 is also adjusted for serum soluble klotho and serum phosphate, and serum calcium corrected for albumin.